Novo Nordisk says STEP Young phase 3 data show 40.4% BMI below threshold
Novo Nordisk announced first STEP Young phase 3 results for once-weekly semaglutide plus a reduced-calorie diet and increased physical activity in children aged 6 to under 12 with obesity.
Bagsværd, Denmark, 7 September 2026 — Novo Nordisk today announced first results from the STEP Young phase 3 trial, which evaluated once-weekly semaglutide alongside a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years old with obesity. The company said Obe…